RSS

Atalante 1

The Independent Data Monitoring Committee (IDMC) has approved the continuation of the Phase III clinical study into OSE Immunotherapeutics’ treatment for Non-Small Cell Lung Cancer (NSCLC) — Tedopi — after immune checkpoint inhibitor treatment. more

News